These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33353838)

  • 1. Targeting SUMO Signaling to Wrestle Cancer.
    Kroonen JS; Vertegaal ACO
    Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUMO, Ubiquitin, UBL Proteins: Implications For Human Diseases - Fifth International Conference.
    Skaug B; Chen ZJ
    IDrugs; 2010 Apr; 13(4):224-7. PubMed ID: 20373248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation.
    Licciardello MP; Müllner MK; Dürnberger G; Kerzendorfer C; Boidol B; Trefzer C; Sdelci S; Berg T; Penz T; Schuster M; Bock C; Kralovics R; Superti-Furga G; Colinge J; Nijman SM; Kubicek S
    Oncogene; 2015 Jul; 34(29):3780-90. PubMed ID: 25263445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
    Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
    Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer.
    Langston SP; Grossman S; England D; Afroze R; Bence N; Bowman D; Bump N; Chau R; Chuang BC; Claiborne C; Cohen L; Connolly K; Duffey M; Durvasula N; Freeze S; Gallery M; Galvin K; Gaulin J; Gershman R; Greenspan P; Grieves J; Guo J; Gulavita N; Hailu S; He X; Hoar K; Hu Y; Hu Z; Ito M; Kim MS; Lane SW; Lok D; Lublinsky A; Mallender W; McIntyre C; Minissale J; Mizutani H; Mizutani M; Molchinova N; Ono K; Patil A; Qian M; Riceberg J; Shindi V; Sintchak MD; Song K; Soucy T; Wang Y; Xu H; Yang X; Zawadzka A; Zhang J; Pulukuri SM
    J Med Chem; 2021 Mar; 64(5):2501-2520. PubMed ID: 33631934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between SUMOylation and NEDDylation regulates RPL11 localization and function.
    El Motiam A; Vidal S; de la Cruz-Herrera CF; Da Silva-Álvarez S; Baz-Martínez M; Seoane R; Vidal A; Rodríguez MS; Xirodimas DP; Carvalho AS; Beck HC; Matthiesen R; Collado M; Rivas C
    FASEB J; 2019 Jan; 33(1):643-651. PubMed ID: 30024791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor.
    He X; Riceberg J; Soucy T; Koenig E; Minissale J; Gallery M; Bernard H; Yang X; Liao H; Rabino C; Shah P; Xega K; Yan ZH; Sintchak M; Bradley J; Xu H; Duffey M; England D; Mizutani H; Hu Z; Guo J; Chau R; Dick LR; Brownell JE; Newcomb J; Langston S; Lightcap ES; Bence N; Pulukuri SM
    Nat Chem Biol; 2017 Nov; 13(11):1164-1171. PubMed ID: 28892090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Ubiquitin-like Modifier Alters IFN Response.
    Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
    J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the loss of SUMO pathway function on cancer cells and tumor proliferation.
    He X; Riceberg J; Pulukuri SM; Grossman S; Shinde V; Shah P; Brownell JE; Dick L; Newcomb J; Bence N
    PLoS One; 2015; 10(4):e0123882. PubMed ID: 25860128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The post-translational modification, SUMOylation, and cancer (Review).
    Han ZJ; Feng YH; Gu BH; Li YM; Chen H
    Int J Oncol; 2018 Apr; 52(4):1081-1094. PubMed ID: 29484374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
    Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
    J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMO pathway components as possible cancer biomarkers.
    Mattoscio D; Chiocca S
    Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review).
    Wang L; Qian J; Yang Y; Gu C
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34368858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
    Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
    Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diversification of SUMO-activating enzyme in Arabidopsis: implications in SUMO conjugation.
    Castaño-Miquel L; Seguí J; Manrique S; Teixeira I; Carretero-Paulet L; Atencio F; Lois LM
    Mol Plant; 2013 Sep; 6(5):1646-60. PubMed ID: 23482370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of biochemically distinct properties of the small ubiquitin-related modifier (SUMO) conjugation pathway in Plasmodium falciparum.
    Reiter K; Mukhopadhyay D; Zhang H; Boucher LE; Kumar N; Bosch J; Matunis MJ
    J Biol Chem; 2013 Sep; 288(39):27724-36. PubMed ID: 23943616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Starting and stopping SUMOylation. What regulates the regulator?
    Watts FZ
    Chromosoma; 2013 Dec; 122(6):451-63. PubMed ID: 23812602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical characterization of SUMO-conjugating enzymes by in vitro sumoylation assays.
    Eisenhardt N; Ilic D; Nagamalleswari E; Pichler A
    Methods Enzymol; 2019; 618():167-185. PubMed ID: 30850051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SUMO targets the APC/C to regulate transition from metaphase to anaphase.
    Eifler K; Cuijpers SAG; Willemstein E; Raaijmakers JA; El Atmioui D; Ovaa H; Medema RH; Vertegaal ACO
    Nat Commun; 2018 Mar; 9(1):1119. PubMed ID: 29549242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
    Yang Y; Xia Z; Wang X; Zhao X; Sheng Z; Ye Y; He G; Zhou L; Zhu H; Xu N; Liang S
    Mol Pharmacol; 2018 Aug; 94(2):885-894. PubMed ID: 29784649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.